Non-Invasive Diagnostic Tests for Bladder Cancer: A Review of the Literature

2005 ◽  
Vol 75 (3) ◽  
pp. 193-200 ◽  
Author(s):  
PierFrancesco Bassi ◽  
Vincenzo De Marco ◽  
Antonello De Lisa ◽  
Mariangela Mancini ◽  
Francesco Pinto ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Diagnostic Tests ◽  
Review Of The Literature ◽  
Non Invasive

302 CLINICAL APPLICATIONS OF BLADDER CANCER MICROARRAY DATA: TOWARDS THE DEVELOPMENT OF NON INVASIVE DIAGNOSTIC TESTS

2009 ◽  
Vol 8 (4) ◽  
pp. 196
Author(s):  
L. Mengual ◽  
M. Burset ◽  
E. Ars ◽  
J.J. Lozano ◽  
H. Villavicencio ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Microarray Data ◽  
Diagnostic Tests ◽  
Clinical Applications ◽  
Non Invasive

scholarly journals Clinical Utility of Oncuria™, a Multiplexed Liquid Biopsy for the Non-Invasive Detection of Bladder Cancer—A Pilot Study

Diagnostics ◽  
2022 ◽  
Vol 12 (1) ◽  
pp. 131
Author(s):  
Kaoru Murakami ◽  
Ian Pagano ◽  
Hideki Furuya ◽  
Timothy Daskivich ◽  
Dave Mori ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Pilot Study ◽  
Diagnostic Tests ◽  
Cancer Surveillance ◽  
Molecular Diagnostic ◽  
International Studies ◽  
Gross Hematuria ◽  
Real World Data ◽  
Non Invasive ◽  
Clinical Scenarios

Oncuria™ is a validated quantitative multiplex immunoassay capable of detecting bladder cancer from a voided urine sample. Herein, we sought to determine whether Oncuria™ affects physicians’ use of non-invasive and invasive diagnostic tests for microhematuria, gross hematuria, and bladder cancer surveillance. We conducted a survey-based study to assess physician management of nine clinical scenarios involving real-world data from patients with gross hematuria, microhematuria, and bladder cancer on surveillance. We randomly sampled 15 practicing urologists and generated data including 135 patient-by-urologist interactions and 2160 decision points. Urologists recommended a selection of diagnostic tests and procedures before and after Oncuria™ results were provided. We assessed changes in provider use of non-invasive and invasive diagnostic tests after Oncuria™ results were provided. Over 90% of all urologists changed their diagnostic behavior in at least one patient case with the addition of Oncuria™ results. The total number of diagnostic procedures was reduced by 31% following the disclosure of a negative Oncuria™ test and 27% following the disclosure of a positive Oncuria™ test. This is pilot study has the potential to shed light on the analysis of our four large multicenter international studies deploying OncuriaTM. The Oncuria™ urine-based test, a molecular diagnostic capable of ruling out the presence of bladder cancer, reduces both unnecessary invasive and non-invasive diagnostics and has the potential to reduce costs and improve patient outcomes.

scholarly journals Spotlight on PSMA as a new theranostic biomarker for bladder cancer

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Maria Maddalena Tumedei ◽  
Sara Ravaioli ◽  
Federica Matteucci ◽  
Monica Celli ◽  
Ugo De Giorgi ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Diagnostic Tests ◽  
Radionuclide Therapy ◽  
Tumor Type ◽  
Prostate Specific Membrane Antigen ◽  
Bladder Tissue ◽  
Tissue Samples ◽  
Specific Membrane ◽  
Psma Expression ◽  
Degree Of Extension

AbstractBladder cancer (BCa) patients are diagnosed by cytology and cystoscopy. However, these diagnostic tests bear some limitations. We sought for reliable biomarkers to better determine BCa extension. Prostate-specific membrane antigen (PSMA) appears to fulfill this requirement in prostate cancer but its role in BCa has not been established yet. We then analyzed 87 bladder tissue samples from 74 patients assessing PSMA expression by immunohistochemistry. The median PSMA expression, exclusively found in tumor neovasculature, in terms of H-score significantly differed between non-tumor samples and tumor samples (p = 0.00288) showing a higher neovasculature-related PSMA expression. No differences were observed in relation to tumor type, grade and stage. BCa neovasculature-related PSMA overexpression may be useful in defining the degree of extension of the neoplasm. In addition, testing PSMA expression by immunohistochemistry may hold theranostic implications both considering anti-angiogenesis agents and radio-labelled PSMA ligands for intracavitary radionuclide therapy. In our opinion, BCa neovasculature-related PSMA overexpression may be considered an apt target for anti-angiogenesis and radionuclide treatment in BCa, once the evaluation of tumor-retention time for the appropriateness of long half-life therapeutic PSMA ligands as radionuclide treatment will be performed.

scholarly journals Epigenomic and Metabolomic Integration Reveals Dynamic Metabolic Regulation in Bladder Cancer

Cancers ◽  
2021 ◽  
Vol 13 (11) ◽  
pp. 2719
Author(s):  
Alba Loras ◽  
Cristina Segovia ◽  
José Luis Ruiz-Cerdá
Keyword(s):  
Bladder Cancer ◽  
Cancer Biology ◽  
Metabolic Regulation ◽  
Tumor Development ◽  
Dna Methyltransferases ◽  
Pentose Phosphate ◽  
Metabolic Reprogramming ◽  
Oncogenic Signaling ◽  
Invasive Approach ◽  
Non Invasive

Bladder cancer (BC) represents a clinical, social, and economic challenge due to tumor-intrinsic characteristics, limitations of diagnostic techniques and a lack of personalized treatments. In the last decade, the use of liquid biopsy has grown as a non-invasive approach to characterize tumors. Moreover, the emergence of omics has increased our knowledge of cancer biology and identified critical BC biomarkers. The rewiring between epigenetics and metabolism has been closely linked to tumor phenotype. Chromatin remodelers interact with each other to control gene silencing in BC, but also with stress-inducible factors or oncogenic signaling cascades to regulate metabolic reprogramming towards glycolysis, the pentose phosphate pathway, and lipogenesis. Concurrently, one-carbon metabolism supplies methyl groups to histone and DNA methyltransferases, leading to the hypermethylation and silencing of suppressor genes in BC. Conversely, α-KG and acetyl-CoA enhance the activity of histone demethylases and acetyl transferases, increasing gene expression, while succinate and fumarate have an inhibitory role. This review is the first to analyze the interplay between epigenome, metabolome and cell signaling pathways in BC, and shows how their regulation contributes to tumor development and progression. Moreover, it summarizes non-invasive biomarkers that could be applied in clinical practice to improve diagnosis, monitoring, prognosis and the therapeutic options in BC.

Lymphopaenia as a predictor of sarcoidosis in patients with a first episode of uveitis

2018 ◽  
Vol 103 (9) ◽  
pp. 1296-1300 ◽  
Author(s):  
Fahriye Groen-Hakan ◽  
Laura Eurelings ◽  
Aniki Rothova ◽  
Jan van Laar
Keyword(s):  
Diagnostic Tests ◽  
Medical Center ◽  
Age At Onset ◽  
Diagnostic Value ◽  
Youden Index ◽  
First Episode ◽  
Operating Characteristics ◽  
Non Invasive ◽  
Erasmus Medical ◽  
Uveitis Attack

Background/aimsThe diagnostic properties of conventional diagnostic tests (ACE and chest radiography) for sarcoidosis-associated uveitis are not ideal. The diagnostic value of lymphopaenia for sarcoidosis-associated uveitis is investigated.MethodsA retrospective study of 191 consecutive patients with a first uveitis episode visiting the ophthalmology department (Erasmus Medical Center, Rotterdam, The Netherlands). Receiver operating characteristics (ROC) analysis was performed and compared with known ROC values from literature of conventional diagnostic tests for sarcoidosis-associated uveitis. An ideal cut-off was determined for lymphopaenia by calculation of the highest Youden index.ResultsOut of all patients with first uveitis attack, 32/191 or 17% were subsequently diagnosed with biopsy-proven or radiological diagnosis of sarcoidosis. Lymphopaenia (<1.5×109/L) was significantly more often observed in patients with sarcoidosis-associated uveitis compared with patients with non-sarcoidosis-associated uveitis (p<0.05). The sensitivity and specificity of lymphopaenia was 75 % and 77 %, respectively. The optimal cut-off for lymphopaenia for diagnosing sarcoidosis-associated uveitis was 1.47 ×109/L. Lymphopaenia resulted in a 12.0 (95% CI 4.7 to 30.5 fold risk for having sarcoidosis, corrected for sex, race and age at onset of uveitis in patients with a first uveitis attack.ConclusionLymphopaenia is a non-invasive and useful marker for diagnosing sarcoidosis-associated uveitis.

scholarly journals Development of 3-Hydroxyanthranilic acid-based Integrated Non-invasive Biosensor for Bladder Cancer Detection

2015 ◽  
Vol 26 (2) ◽  
pp. S47-S48
Author(s):  
Yuh-Shyan Tsai ◽  
Yeong-Chin Jou ◽  
Yen-Ping Tsai ◽  
Bin-Da Liu ◽  
Hung-In Lin ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Cancer Detection ◽  
Non Invasive ◽  
Hydroxyanthranilic Acid
Sign in / Sign up

Export Citation Format

Share Document